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Abstract
Background: Progressive resistance exercise training (PRT) improves physical functioning in patients with HIV infection.
Creatine supplementation can augment the benefits derived from training in athletes and improve muscle function in
patients with muscle wasting. The objective of this study was to determine whether creatine supplementation augments
the effects of PRT on muscle strength, energetics, and body composition in HIV-infected patients.
Methodology/Principal Findings: This is a randomized, double blind, placebo-controlled, clinical research center-based,
outpatient study in San Francisco. 40 HIV–positive men (20 creatine, 20 placebo) enrolled in a 14-week study. Subjects were
randomly assigned to receive creatine monohydrate or placebo for 14 weeks. Treatment began with a loading dose of 20 g/
day or an equivalent number of placebo capsules for 5 days, followed by maintenance dosing of 4.8 g/day or placebo.
Beginning at week 2 and continuing to week 14, all subjects underwent thrice-weekly supervised resistance exercise while
continuing on the assigned study medication (with repeated 6-week cycles of loading and maintenance). The main
outcome measurements included muscle strength (one repetition maximum), energetics (31P magnetic resonance
spectroscopy), composition and size (magnetic resonance imaging), as well as total body composition (dual-energy X-ray
absorptiometry). Thirty-three subjects completed the study (17 creatine, 16 placebo). Strength increased in all 8 muscle
groups studied following PRT, but this increase was not augmented by creatine supplementation (average increase 44 vs.
42%, difference 2%, 95% CI 29.5% to 13.9%) in creatine and placebo, respectively). There were no differences between
groups in changes in muscle energetics. Thigh muscle cross-sectional area increased following resistance exercise, with no
additive effect of creatine. Lean body mass (LBM) increased to a significantly greater extent with creatine.
Conclusions / Significance: Resistance exercise improved muscle size, strength and function in HIV-infected men. While creatine
supplementation produced a greater increase in LBM, it did not augment the robust increase in strength derived from PRT.
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Introduction
In people with HIV infection and other chronic diseases,
maintenance or augmentation of muscle mass is important for
preserving functional status and forestalling disease progression [1].
Progressive resistance exercise training (PRT), either alone or in
combination with aerobic exercise training, can increase muscle mass
and improve physical performance in persons with HIV infection [2–
10]. Many individuals employ so-called ergogenic aids, including
substances such as anabolic steroids and growth hormone, to facilitate
muscle accrual, and to enhance the anabolic effect of PRT on body
composition with a view to both functional and aesthetic improve-
ments [11,12]. Creatine monohydrate is a nutritional supplement
that has been shown to enhance short-term energy availability during
intense exercise and to improve recovery between intense exercise
bouts [13,14]. Based on such findings, it is being used by competitive
and recreational athletes as an ergogenic aid to improve their training
efficiency. Although in some populations creatine supplementation
has been shown to improve isotonic strength [15], torque [16] and
power [17] other studies have failed to show any such effects [18–21].
To date, there have been no specific studies of the efficacy of the
medical use of creatine supplementation in people with HIV
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infection. Further, the effects of creatine supplementation in
combination with PRT on muscle energetics (e.g. mitochondrial
function, resistance to fatigue, or intramuscular fat content) are not
known in the HIV population, even though these are considered
the primary benefits of creatine supplementation. The present
study was designed to test the hypothesis that the medical use of
creatine supplementation would augment increases in muscle
strength derived from PRT in HIV-positive adults. The functional
impact and potential mechanisms of these strength gains were also
assessed.
Methods
Protocol
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics
The study was approved by the Committees on Human
Research at the University of California San Francisco and the
San Francisco VA Medical Center. All subjects gave written
informed consent.
Participants
Forty-three clinically-stable, sedentary HIV-positive subjects (42
men, 1 woman) living in the San Francisco Bay area were recruited
by our study coordinators and studied between August 2001 and
January 2004 (Figure 1). Subjects using antiretroviral therapy (ART)
were required to be on stable regimens for at least 30 days before
enrollment and were asked to remain so during the study. Subjects
who had received no ART for the preceding 30 days and had no
plans to initiate therapy during the study were also eligible.
Exclusion criteria included regular resistance exercise training, use
of anabolic hormones and other putative ergogenic aids (e.g. amino
acids, protein supplements, b-agonists), serum creatinine .1.5 mg/
dl; history of renal disease; creatine kinase (CK).1.5 times the upper
limit of normal (ULN); hemoglobin,8.5 g/dl; liver transaminase or
lactate dehydrogenase levels $56ULN; uncontrolled diarrhea,
nausea, or vomiting; impaired oral food intake; untreated hypogo-
nadism; pharmacologic use of anabolic or immune modulating
therapies; systemic infection within 30 days; history of heart disease;
and current pregnancy or lactation. Subjects on stable testosterone
replacement for $6 months were eligible.
Sample Size
Sample size calculations were based on other studies with
similar design and allow for a detection of standardized effect sizes
Figure 1. CONSORT Diagram showing the disposition of subjects randomized to receive creatine monohydrate or an equivalent
number of placebo capsules for 14 weeks.
doi:10.1371/journal.pone.0004605.g001
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of 0.9 with 80% power to detect changes in intramuscular
phosphocreatine (PCr) levels.
Randomization
Subjects were randomized, in a blinded 1:1 fashion, to receive
identical-appearing capsules containing either pure creatine
monohydrate or placebo (both provided by Jarrow Universal
Herbs Inc., Union City, CA) for 14 weeks (Figure 1). A computer-
generated randomization list was prepared by a statistical
consultant and given directly to the research pharmacy at San
Francisco General Hospital (SFGH), where the capsules were
bottled and dispensed. All data were collected and analyzed
without knowledge of treatment assignment.
Three subjects (1 creatine, 2 placebo), including the one
woman, withdrew after randomization but before baseline testing
or initiation of treatment and are thus excluded from the analysis.
Intervention
Subjects began with a loading dose of 20 g/day (divided among
four doses) or an equivalent number of placebo capsules for 5 days,
followed by maintenance dosing of 4.8 g/day (in two 2.4 g doses)
or placebo. Maintenance dosing was interrupted briefly for
additional 5-day loading cycles at the beginning of weeks 7 and
13. This dosing regimen is similar to those employed in several
recent studies (as reviewed by Nissen [13]). Subjects were given a
non-caffeinated fruit juice beverage containing 20 g of simple
carbohydrate to take with each dose of study medication [22].
Training Regimen. After two weeks, all subjects began a 12-
week program of supervised PRT, while continuing on their
assigned study medication. Training was performed using a Hoist
5000 Multi-Gym Fitness System (San Diego, CA). Subjects
exercised for 1K hours 3 days weekly for 12 weeks. The training
included ankle dorsiflexion, ankle plantar flexion, ankle plantar
flexion with bent knee, leg press, leg curls, pec decks chest exercises,
tricep pushdown, bicep curl and three types of abdominal crunches.
Strength in each muscle group was assessed by the one repetition
maximum (1RM) test [23] except in the rectus abdominus, in which
the number of sit-ups performed in 30 seconds was recorded. Each
training session included 4 sets of 8 repetitions at 80% of the 1RM
for each exercise. The 1RM for each exercise was reassessed once
every two weeks and training intensity adjusted to maintain 80% of
the 1RM. All measurements were performed after two days of rest
in absence of any symptoms of muscle soreness or fatigue.
Objectives
The primary aim was to compare the changes in muscle
strength (1RM, sit-ups and MVC) from week 0 to week 14 in the
two treatment groups. Secondary aims were to compare changes
in muscle size, composition, energetics and fatigue, as well as body
composition and biochemistry.
Outcome Measurements
Subjects were studied in the General Clinical Research Center
(GCRC) at SFGH and in the Magnetic Resonance Unit at the San
Francisco VA Medical Center. Height and weight were recorded
with subjects wearing a hospital gown. Measurements of muscle
strength, size, composition, energetics and fatigue, as well as body
weight and composition and serum biochemistries, were made at
baseline, after two weeks of treatment with creatine or placebo
(before PRT began), and again after 12 weeks of PRT (study week
14). Safety was monitored throughout the study.
Muscle Energetics and Fatigue. Non-invasive measures of
intracellular phosphocreatine (PCr), inorganic phosphorous (Pi),
and pH were obtained from the dorsiflexor muscle of the right ankle
by 31P magnetic resonance spectroscopy (MRS) using a 30-cm bore
1.9 T superconducting Oxford magnet, as described in detail
elsewhere [24,25]. Subjects performed two contraction protocols on
the same day, separated by 20 minutes of rest. The first protocol
consisted of a 15-second maximum voluntary contraction (MVC),
which was used to determine the muscle’s capacity for oxidative
phosphorylation [24] reported as the half-time (T1/2) of PCr
recovery following the contraction. The recovery analysis indicated
that our MRS system can detect PCr changes of 0.5 mM. The
second protocol was used to assess muscle function during high-
intensity, fatiguing conditions. Muscle force and energetics were
measured simultaneously during 36 consecutive MVCs over
6 minutes, one every 10 seconds. The fatigue profile was
calculated as described by Karatzaferi et al [26].
Dorsiflexor Strength. Isometric MVC force was recorded
during ankle dorsiflexion while the leg was positioned in the
magnet for the MRS studies [24,25] The highest force from the 3
MVCs was used to quantify dorsiflexion strength [24] and scale
performance during the aforementioned fatigue task.
Muscle Size and Composition. Proton T1-weighted magnetic
resonance imaging (MRI) was used to visualize the cross-sectional
area (CSA) of the thigh and calf using a 1.5 T whole body Siemens
Magnetom Vision System, as described previously [24]. Data were
analyzed using a customized software program (Interactive Data
Language Research Systems, Inc., Boulder, CO). The coefficient of
variation of muscle CSA measurements was 0.6%.
Body Composition. Whole body and regional fat and lean
body mass (LBM) were measured using a Lunar model DPX dual
energy x-ray absorptiometer (DEXA) (Madison, WI) [27,28].
Biochemical Measurements. Fasting blood samples were
collected for determination of plasma creatine and lactate and
serum creatinine, creatine kinase (CK), lipid, glucose, and insulin
levels. Plasma creatine was determined by liquid chromatography
– tandem mass spectrometry (LC/MS) using a Surveyor LC
interfaced with a TSQ Quantum Ultra triple-stage quadrupole
MS (Thermo-Finnigan, San Jose, CA) operated in the positive ion
mode using atmospheric pressure chemical ionisation.
Quantitation was achieved using selected reaction monitoring of
the transitions m/z 114 to m/z 44 for creatine and m/z 117 to m/
z 47 for the internal standard. The lower limit of quantitation was
2 mg/mL (18 mmol/L). Intra-day precision ranged from 3.2% to
8.9%, and recovery from 100.3% to 103.4%. Plasma lactate was
measured using a YSI STAT2300 analyzer (Yellow Springs, OH),
and serum insulin by radioimmunoassay (Linco Research Inc., St.
Charles, MO) in the GCRC Core Laboratory. The remaining
assays were performed in the SFGH Clinical Laboratories. Insulin
resistance was calculated by homeostasis model assessment
(HOMA-IR [29]).
Safety. Serum creatinine and CK levels were monitored
biweekly. Study medication was suspended for one week if
creatinine levels increased to .1.8 mg/dl or CK to .450 U/
liter. If, after one week, creatinine and/or CK levels returned to
baseline levels, study medication was resumed at half of the initial
dosing level and creatinine and/or CK levels were monitored
weekly. If creatinine and/or CK levels again exceeded the
aforementioned values, study drug was discontinued but subjects
continued on study (including exercise). If subjects complained of
soreness, the workload for the affected muscle group(s) was
reduced until the soreness resolved.
Statistical Analysis
All safety analyses were performed on an intent-to-treat basis in
all 40 subjects who underwent baseline testing. Efficacy analyses
Creatine and HIV+ Patients
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were performed in the evaluable subset, defined as the number of
subjects assigned to each treatment in whom paired results
(baseline to week 2, baseline to week 14) were available. The
numbers of subjects in whom these results are available are
indicated in each table.
Within-group changes from baseline to week 2 and baseline to
week 14 were evaluated using paired t-tests. Absolute changes
(week 0 to week 2 and week 0 to week 14) in the creatine group
were compared with those in the placebo group using unpaired t-
tests, and the 95% confidence interval for the differences between
mean changes calculated. All statistical analyses were performed
using Statview (SAS Institute Inc. Cary, NC). Data are the mean
and (SD). Two-tailed p-values ,0.05 were considered statistically
significant. Non-parametric analyses were also performed and
yielded similar results.
Results
Subjects
Of the 40 subjects (20 creatine, 20 placebo) who underwent
baseline testing and received at least one dose of study medication,
25% were African-American, 15% Hispanic, and 60% Caucasian.
There were no differences between groups in age, racial
distribution, BMI, CD4 count, years of known HIV infection, or
in the classes of ART used (Table 1).
Follow-up and Adherence to Study Treatments
Thirty-three subjects (83%) completed the study. Seven subjects
(3 creatine, 4 placebo) withdrew for the following reasons:
hypersensitivity reaction (1 creatine), schedule conflicts (2
creatine), family emergency (1 placebo), and non-adherence
(missing three consecutive PRT sessions [3 placebo]). Subjects
who completed the study attended 95% of their training sessions.
Adherence to the treatment regimen was evidenced by the fact
that plasma creatine levels increased substantially in all subjects
who were receiving creatine at week 14 (see below).
Effects on muscle strength
At baseline, all measures of strength were similar in the two
study groups (Table 2). At week 14, average 1RM strength
increased in all muscle groups (Table 2, Fig. 2). Contrary to our
hypothesis, the magnitude of the increase in strength was not
greater with creatine (average increase 44% for creatine and 42%
for placebo, difference 2%, 95% CI29.5% to 13.9%; P= 0.58). In
addition, the rate of strength gain did not differ between groups.
Dorsiflexor muscle isometric strength (MVC) did not change
significantly in either group (Table 2).
Effects on muscle energetics and fatigue
All measures of muscle energetics, including muscle oxidative
capacity, were similar across groups at all time points, and were
not significantly affected by creatine supplementation (Table 2).
Likewise, the fatigue profile (the rate of force decline during the 6-
minute exercise protocol) did not differ between or within the two
groups at any time point (data not shown). Among subjects
randomized to creatine, there was a weak association between
changes in plasma creatine levels and changes in resting PCr
(r = 0.53, P = 0.09) and no relationship with post-exercise PCr. In
the two treatment groups combined, PCr recovery following 15-
sec MVC improved significantly after PRT (T1/2 =23.89 [20.04
to 27.74] seconds, P = 0.047).
Effects on body composition
Body weight and composition were similar at baseline (Table 3).
By week 14, LBM had increased in both groups, with a greater
increase in the creatine group (P = 0.01). Body weight increased
only in the creatine group. No differences between groups were
noted in total, trunk or limb fat content at any time point.
Thigh muscle CSA increased in both groups at week 14, but the
magnitude of the increase did not differ significantly between
groups. There were no changes in calf CSA in either group.
Likewise, no changes in muscle or subcutaneous fat were noted at
any time point in either treatment group.
Biochemical and safety measures
There were no significant differences between groups in
biochemical parameters at baseline (Table 4). Average plasma
creatine levels increased significantly in the creatine group, with no
change in those on placebo (P#0.001 vs. placebo). Serum
creatinine concentrations increased more with creatine than
placebo (P= 0.001 and 0.002 at weeks 2 and 14, respectively).
Triglycerides increased with creatine at week 14 (P= 0.04 vs.
placebo). Total cholesterol decreased significantly in the placebo
group at week 14, but the difference between groups was not
statistically significant. At week 2, both insulin and HOMA-IR
decreased transiently in the creatine group (P= 0.04 and 0.05 vs.
placebo, respectively). There were no differences in lactate, glucose
or CK levels between or within groups at any time point.
With regard to the pre-defined toxicity management guidelines,
4 subjects, all in the creatine group, experienced increases in
serum creatinine levels to .1.8 mg/dL. In all four cases,
creatinine levels had returned to ,1.8 mg/dL at week 14. CK
levels increased to .450 U/liter 18 times in 14 subjects (10 on
placebo and 4 on creatine). The increases were transient and likely
related to exercise, and all had resolved by week 14.
Discussion
In the present study, we found that PRT consistently increased
muscle strength in HIV-infected men (Fig. 2). Although subjects
receiving creatine supplementation had a greater increase in LBM
Table 1. Baseline Characteristics of the Study Population.
Creatine Placebo
N 20 20
Age (yrs) 44 (9) 44 (8)
BMI (kg/m2) 23.7 (2.6) 23.7 (2.5)
Total body fat (%) 18.4 (6.7) 16.0 (5.3)
Testosterone (ng/dl) 725 (295) 597 (217)
Yrs since HIV diagnosis 10 (7) 10 (5)
CD4 (cells/ml) 448 (310) 460 (278)
Current antiretroviral therapy:
PI (%) 40 35
NRTI (%) 80 75
NNRTI (%) 30 30
No Antiretroviral (%) 20 35
Subject characteristics at baseline according to the assigned study medication.
Data are mean (SD).
Abbreviations: PI, protease inhibitor; NRTI, nucleoside analogue reverse
transcriptase inhibitors; NNRTI, non-nucleoside analogue reverse transcriptase
inhibitors.
doi:10.1371/journal.pone.0004605.t001
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Table 2. Muscle Strength and Energetics at Baseline and Changes on Study.
Baseline
Changes wk 0
to wk 2
Changes wk
0 to wk 14
Differences between groups Mean
changes (95% CI)
Creatine Placebo Creatine Placebo Creatine Placebo Wk 0 to Wk 2 Wk 0 to Wk 14
Strength in individual muscle groups:
N 20 20 19 19 17 16 N/A N/A
Ankle Dorsiflexion (lbs) 90 (21) 101 (21) 5 (8) 6 (12) 60 (26)* 59 (27)* 21 (8 to 5) 1 (218 to 20)
Ankle Plantar Flexion (lbs) 176 (44) 174 (37) 15 (21) 6 (17) 80 (39)* 68 (54)* 9 (23 to 22) 12 (222 to 45)
Ankle Plantar Flexion Bent Knee (lbs) 207 (71) 176 (56) 10 (19) 23 (29) 64 (46)* 106 (67)* 213 (229 to 3) 242 (283 to 1)
Leg Presses (lbs) 248 (55) 245 (54) 2 (17) 14 (29) 66 (56)* 75 (49)* 212 (228 to 4) 29 (247 to 27)
Leg Curls (lbs) 106 (26) 113 (22) 6 (10) 4 (14) 43 (22)* 38 (27)* 3 (25 to 11) 5 (213 to 22)
Pec Deck (lbs) 88 (23) 94 (26) 3 (9) 3 (6) 35 (15)* 32 (14)* 0 (25 to 4) 2 (28 to 12)
Biceps Pushdown (lbs) 51 (14) 51 (12) 1 (4) 1 (6) 14 (10)* 12 (9)* 0 (24 to 4) 2 (25 to 9)
Triceps Curls (lbs) 53 (10) 54 (11) 2 (3) 1 (6) 16 (8)* 14 (8)* 1 (22 to 4) 2 (24 to 7)
Abdominal Crunches (rep) 19 (5) 17 (5) 1 (2) 1 (3) 8 (4)* 9 (5)* 0 (21 to 2) 21 (24 to 2)
MVC (N) 241 (53) 240 (61) 21 (67) 27 (51) 9 (38) 39 (50) 228 (276 to 9) 230 (265 to 5)
Lower Leg Flexion (N = 16) (N = 18) (N = 12) (N = 14) (N = 13) (N = 14)
Muscle function (31P MRS): 15-second maximal voluntary contraction (MVC) protocol:
N 17 17 13 12 14 13 N/A N/A
At rest (before MVC):
PCr (mM) 37 (2) 36 (3) 21 (3) 0 (3) 0 (3) 0 (2) 21 (23 to 1) 0 (22 to 2)
Pi (mM) 5.8 (2.3) 6.1 (2.6) 0.7 (2.9) 20.4 (2.6) 0.2 (2.9) 0.2 (2.4) 1.1 (21.2 to 3.5) 0.1 (22.0 to 2.2)
PCr/Pi 7.6 (3.7) 7.3 (3.6) 20.3 (6.1) 0.4 (4.8) 0.5 (6.8) 21.1 (4.0) 20.7 (25.3 to 3.8) 1.6 (22.9 to 6.1)
pH 7.15(0.06) 7.12(0.05) 20.04(0.07) 20.02(0.06) 20.03(0.06) 20.02(0.05) 20.02(20.08 to 0.03) 20.01(20.06 to 0.03)
Immediately following a 15-sec MVC:
PCr (mM) 18 (4) 16 (5) 22 (6) 21 (5) 22 (5) 21 (8) 21 (25 to 4) 21 (26 to 5)
% of resting PCr 48 (11) 44 (13) 24 (15) 24 (10) 24 (12) 23 (21) 0 (211 to 10) 21 (214 to 13)
Pi (mM) 23 (6) 25 (6) 2 (8) 2 (4) 22 (6) 0 (8) 0 (25 to 6) 22 (28 to 4)
PCr/Pi 0.9 (0.5) 0.7 (0.3) 0.1 (0.5) 20.1 (0.3) 0.0 (0.5) 0.0 (0.5) 0.0 (20.4 to 0.3) 0.0 (20.4 to 0.4)
pH 7.09 (0.23) 7.06 (0.13) 20.11 (0.26) 0.03 (0.20) 20.02 (0.38) 0.01 (0.13) 20.14(20.34 to 0.05) 20.03(20.26 to 0.20)
PCr recovery (t1/2, sec) 30 (9) 29 (12) 22 (12) 21 (15) 24 (9) 24 (16) 21 (212 to 11) 0 (210 to 11)
Muscle function (31P MRS): 6 minute exercise protocol:
N 15 15 10 10 12 10 N/A N/A
At rest :
PCr (mM) 37 (3) 37 (2) 21 (3) 21 (3) 0 (2) 0 (3) 0 (23 to 3) 0 (22 to 3)
Pi (mM) 5.4 (2.6) 5.1 (2.4) 0.9 (3.5) 0.7 (2.9) 20.4 (1.9) 20.1 (3.1) 0.1 (22.8 to 3.1) 20.3 (22.6 to 2.0)
PCr/Pi 10.0 (8.0) 9.6 (5.9) 22.7 (7.6) 22.1 (4.3) 20.9 (7.6) 0.9 (6.5) 20.6 (26.4 to 5.2) 21.8 (28.2 to 4.6)
pH 7.13(0.08) 7.09(0.06) 20.03(0.08) 0.02(0.10) 0.02(0.09) 0.03(0.09) 20.05(20.13 to 0.04) 20.01(20.09 to 0.07)
Immediately following the 6-minute exercise protocol:
PCr (mM) 8 (7) 7 (4) 2 (6) 21 (4) 21 (6) 21 (5) 3 (22 to 7) 0 (25 to 5)
% of resting PCr 23 (20) 19 (11) 5 (16) 23 (10) 22 (15) 22 (14) 8 (25 to 20) 0 (213 to 13)
Pi (mM) 33 (8) 35 (5) 0 (8) 2 (4) 1 (8) 1 (7) 22 (28 to 4) 0 (27 to 7)
PCr/Pi 0.4 (0.5) 0.2 (0.2) 0.1 (0.3) 20.1(0.1) 0.0 (0.4) 0.0 (0.2) 0.2 (0.0 to 0.4) 0.0 (20.3 to 0.4)
pH 6.67(0.16) 6.67(0.25) 20.06 (0.18) 0.04(0.12) 20.03 (0.21) 0.07 (0.13) 20.02(20.16 to 0.13) 20.10(20.26 to 0.06)
PCr recovery (t1/2, sec) 36 (16) 46 (18) 21 (28) 22 (15) 21 (17) 210 (20) 1 (221 to 22) 9 (27 to 25)
Data are mean (SD). The mean differences and the 95% confidence intervals between treatment groups of the changes from baseline at weeks 2 and 14 were
determined by unpaired t-tests. Asterisks (*) are used to indicate within-group changes from baseline that are statistically significant by paired t-test (P,0.05).
Strength was measured as the 1 repetition maximum (1RM) for each muscle group (in pounds) except for the rectus abdominus, in which strength was assessed as the
number of sit-ups completed in 30 seconds; and maximum voluntary contraction (MVC, in Newtons) of the tibialis anterior muscle, which was assessed during
dorsiflexion of the right foot. Muscle function was evaluated using two exercise protocols that were performed inside a 1.9T magnet. The first protocol consisted of a 15-
second maximum voluntary contraction (MVC) that was used to assess the rate of PCr recovery (an index of oxidative capacity). The second protocol consisted of 36
consecutive MVCs, one every 10 seconds, with cycles of 6 seconds of contraction and 4 seconds of relaxation. This latter protocol was used to assess muscle fatigue.
Abbreviations: Rep, Repetitions; PCr, phosphocreatine; Pi, inorganic phosphate; PCr recovery (t K), time needed to recover half of the baseline PCr value.
doi:10.1371/journal.pone.0004605.t002
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than those on placebo, our results provided no evidence that
creatine augmented the increase in strength derived from PRT.
Thus, the increase in LBM in the creatine group was of no
measurable functional benefit. Moreover, using 31P-MRS, we
found no difference between groups in skeletal muscle energy
metabolism at rest, during or following muscle contractions, or in
the fatigue profile. Overall, these data indicate that PRT is a
highly effective means of increasing strength in individuals with
HIV infection, but supplementation with creatine, though safe,
confers no additional increase in strength in this population.
Other studies of creatine supplementation have provided mixed
results. In studies of healthy volunteers, short-term creatine
supplementation (5–30 days) increased muscle size [30] and
indices of short-term high intensity exercise performance,
including muscle strength and power output [31,32] as well as
intramuscular PCr levels assessed by both 31P-MRS [33] and
biopsy [34]. Chronic use of creatine (up to 12 months) has been
associated with increases in total body weight [35,36]. In contrast,
other studies have failed to demonstrate a positive effect of creatine
supplementation on strength, body composition or muscle energy
metabolism [18–21]. The responses to creatine supplementation in
patients with chronic diseases have been similarly mixed, with
some studies showing positive effects [37–42] and others showing
no benefit [43–46].
The pre-treatment PCr concentrations observed in the current
study are consistent with those in the same muscle in healthy
young and older adults [24], suggesting that no deficiency of PCr
existed in this group of HIV-positive subjects. Although other
studies have shown that creatine supplementation increased PCr
levels in healthy adults with normal baseline levels [47] we saw no
such increase in our subjects with HIV infection. We followed a
protocol for creatine loading and maintenance that had been
successfully applied in previous studies [13]. In view of the
potential role of carbohydrate availability and insulin in
stimulating the transport of creatine into muscle cells [22], we
provided subjects with beverages containing 20 g of carbohydrate
for consumption with each dose of study medication. Importantly,
we raised plasma creatine to levels seen in previous studies [48].
Nonetheless, we saw no change in intramuscular PCr concentra-
tion at rest or following exercise. It is possible that factors specific
to HIV infection or its therapies may account for this failure. For
example, some HIV protease inhibitors inhibit glucose uptake by
skeletal muscle [49,50] and might have also interfered with
creatine uptake into muscle. In addition use of another
antiretroviral agent, zidovudine, has been associated with an
accelerated rate of depletion of PCr during exercise in HIV-
infected subjects [51] and may have had a similar effect in our
population. An assessment of the effects of specific antiretroviral
medications on outcome measures was not possible in view of the
relatively small size of our study.
In our study, administration of creatine for two weeks prior to the
exercise intervention was associated with a modest increase in thigh
CSA that approached a level of statistical significance (p= 0.06 vs.
placebo). Likewise, subjects in the creatine group had a significantly
greater increase in LBM following exercise training (p= 0.01 vs.
placebo). Since these changes were not accompanied by increases in
muscle strength or improvement in indices of muscle fatigue or
mitochondrial energy metabolism, it is conceivable that the
increases in CSA and LBM could be explained by increases in
muscle water content, rather than functional muscle mass. Indeed,
increases in muscle water content during creatine treatment have
been reported in prior studies [52]. An increase in water content in
muscle may precede increases in muscle protein synthesis, which
may confer functional (fitness) and physiological (e.g. glucose
disposal) benefits with a longer period of follow-up. Moreover,
increasing muscle size may be considered to be desirable in persons
using creatine and exercise for aesthetic purposes.
All subjects showed robust increases in strength in eight
important muscle groups following 12 weeks of PRT. These
results provide further evidence of the beneficial effects of PRT in
Figure 2. Muscle strength before and after 14 weeks of study. Large rectangles represent the average values, while smaller rectangles
individual data before and after creatine supplementation. Similarly, large circles represent the average values, while smaller circles individual data
before and after placebo supplementation. Data are the sum of strength (1 RM) in 8 muscle groups in subjects randomized to receive creatine
monohydrate or placebo. Strength increased significantly within each treatment group (P,0.01), but there was no significant difference between
groups in the magnitude of the increase (average increase 44 and 42% (difference 2%, 95% CI 29.5% to 13.9%) in creatine and placebo, respectively,
P = 0.58).
doi:10.1371/journal.pone.0004605.g002
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individuals with HIV infection, as has been reported previously in
smaller studies [2–10]. In addition, the rate of PCr recovery
following a 15-second MVC improved in the group as a whole. At
baseline, average PCr recovery rate (T1/2) was 29 seconds, which
is approximately 24% slower than those of healthy young and old
adults studied with the same apparatus and using comparable
methodology [24]. Following training, PCr recovery rates
approached those in healthy untrained adults (TK<23 se-
conds[24]). Because PCr recovery under the conditions applied
in the present study reflects the capacity for oxidative phosphor-
ylation, these data suggest that PRT improved mitochondrial
energy metabolism in patients with HIV infection. Overall, these
benefits provide further evidence that persons with HIV infection
can adapt to a demanding exercise-training program.
Table 3. Body Composition at Baseline and Changes on Study.
Baseline Changes wk 0 to wk 2 Changes wk 0 to wk 14
Differences between groups Mean
changes (95% CI)
Creatine Placebo Creatine Placebo Creatine Placebo Wk 0 to Wk 2 Wk 0 to Wk 14
N 20 20 19 19 17 16 N/A N/A
DEXA Results (kg)
Lean body mass 56.0 (7.3) 57.4 (6.6) 0.9 (1.9) 0.4 (1.2) 2.3 (1.4)* 0.9 (1.4)* 0.5 (20.5 to 1.5) 1.4 (0.3 to 2.4)
Limb (arm+leg) LBM 25.5 (3.8) 26.2 (3.4) 0.6 (0.9)* 20.0 (0.7) 1.1 (0.9)* 0.7 (1.1)* 0.7 (0.1 to 1.3) 0.5 (20.3 to 1.2)
Total body fat 13.7 (6.4) 11.8 (4.8) 0.2 (0.8) 0.2 (0.7) 0.3 (1.8) 0.4 (2.0) 20.0 (20.5 to 0.4) 20.0 (21.4 to 1.3)
Trunk fat 8.2 (4.0) 6.7 (3.1) 0.0 (0.5) 0.1 (0.5) 0.0 (1.2) 0.3 (1.5) 20.2 (20.5 to 0.1) 20.3 (21.2 to 0.7)
Limb (arm+leg) fat 4.8 (2.2) 4.5 (1.8) 0.2 (0.4) 0.0 (0.3) 0.2 (0.6) 0.0 (0.6) 0.2 (20.1 to 0.4) 0.2 (20.2 to 0.6)
MRI Results
Thigh muscle CSA (cm2) 136.7 (24.0) 142.9 (18.3) 4.3 (4.8) 0.7 (4.8) 12.2 (7.8)* 9.3 (8.1)* 3.6 (20.0 to 7.3) 2.9 (23.3 to 9.1)
Thigh % EMCL 4.2 (1.3) 4.9 (2.1) 20.1 (1.4) 20.6 (1.6) 20.1 (1.5) 21.0 (2.3) 0.6 (20.6 to 1.7) 0.9 (20.6 to 2.4)
Thigh SAT area (cm2) 36.2 (18.7) 38.6 (20.3) 20.8 (2.9) 2.4 (13.5) 20.5 (4.1) 4.7 (14.6) 23.2 (210.3 to 3.9) 25.2 (213.1 to 2.7)
Calf muscle CSA (cm2) 74.7 (12.7) 73.9 (13.3) 0.2 (2.6) 20.1 (2.8) 1.5 (3.8) 0.1 (3.5) 0.3 (21.7 to 2.2) 1.4 (21.4 to 4.1)
Calf % EMCL 4.7 (1.6) 4.6 (1.9) 0.8 (1.7) 0.5 (1.9) 1.1 (1.9) 0.9 (2.0) 0.3 (21.0 to 1.6) 0.2 (21.2 to 1.7)
Calf SAT area (cm2) 8.2 (5.6) 7.6 (5.4) 20.3 (1.6) 0.6 (2.1) 0.2 (1.3) 0.4 (0.7) 20.9 (22.2 to 0.4) 20.2 (21.0 to 0.6)
Data are mean (SD). Limb fat is the sum of fat in the arms and legs. The mean differences and 95% confidence intervals between treatment groups of the changes from
baseline at weeks 2 and 14 were determined by unpaired t-tests. Differences between groups in changes from baseline that are statistically significant (P,0.05) are
highlighted in bold. Asterisks (*) are used to indicate within-group changes from baseline that are statistically significant by paired t-test (P,0.05).
Abbreviations: DEXA, dual energy X-ray absorptiometry; MRI, magnetic resonance imaging; CSA, cross-sectional area; SAT, subcutaneous adipose tissue; EMCL,
extramyocellular fat (fat infiltration).
doi:10.1371/journal.pone.0004605.t003
Table 4. Safety and Biochemical Measurements at Baseline and Changes on Study.
Baseline Changes wk 0 to wk 2 Changes wk 0 to wk 14
Differences between groups Mean changes
(95% CI)
Creatine Placebo Creatine Placebo Creatine Placebo Wk 0 to Wk 2 Wk 0 to Wk 14
N 20 20 19 19 17 16 N/A N/A
Plasma creatine (mg/mL) 4.6 (1.4) 4.6 (2.2) 26.0 (25.5)* 20.4 (1.4) 22.1 (18.0)* 21.4 (1.4)* 26.4 (12.9 to 39.8) 23.5 (13.6 to 33.4)
Serum creatinine (mg/dL) 1.0 (0.2) 1.0 (0.1) 0.2 (0.2) 0.0 (0.1) 0.2 (0.2) 0.1 (0.1) 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.3)
Creatine kinase (U/L) 111 (51) 147 (75) 20 (57) 215 (84) 20 (61) 8 (64) 35 (213 to 84) 12 (233 to 57)
Triglycerides (mg/dL) 169 (89) 222 (199) 91 (362) 65 (199) 78 (165) 218 (75) 26 (2166 to 218) 96 (4 to 188)
Cholesterol (mg/dL) 183 (47) 185 (46) 1 (19) 24 (23) 26 (22) 210 (18)* 4 (210 to 18) 4 (21 to 19)
Lactate (mmol/L) 1.4 (0.7) 1.1 (0.4) 0.0 (0.9) 0.0 (0.5) 0.0 (1.1) 20.1 (0.7) 20.1 (20.5 to 0.4) 20.1 (20.8 to 0.6)
Glucose (mg/dL) 94 (12) 90 (9) 22 (12) 21 (9) 26 (14) 0 (8) 21 (28 to 6) 26 (214 to 3)
Insulin (mIU/mL) 15.9 (5.9) 14.3 (5.2) 21.6 (6.1) 3.0 (6.6) 1.2 (10.5) 2.7 (7.3) 24.6 (29.1 to 20.2) 21.5 (28.1 to 5.1)
HOMA-IR 3.6 (1.2) 3.3 (1.5) 20.5 (1.5) 0.6 (1.5) 0.2 (2.5) 0.6 (1.7) 21.0 (22.0 to 0.0) 20.4 (22.0 to 1.2)
Data are the mean (SD). All measurements were performed under fasting conditions. The significance of differences between treatment groups in the changes from
baseline at weeks 2 and 14 was determined by unpaired t-tests, and differences that are statistically significant (P,0.05) are highlighted in bold. Asterisks (*) are used to
indicate within-group changes from baseline that are statistically significant by paired t-test (P,0.05).
Abbreviations: HOMA-IR: Homeostasis model assessment of insulin resistance (20).
To convert to SI units: creatine mg/mL to mmol/L multiply by 7.625; creatinine mg/dL to mmol/L multiply by 88.4; triglycerides mg/dL to mmol/L multiply by 0.01129;
cholesterol mg/dL to mmol/L multiply by 0.02586; glucose mg/dL to mmol/L multiply by 0.05551; insulin mIU/mL to pmol/L multiply by 7.175.
doi:10.1371/journal.pone.0004605.t004
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Because HIV-infected persons on ART are at risk of developing
metabolic and morphologic abnormalities, including peripheral
lipoatrophy [53], we examined the effects of creatine supplemen-
tation and PRT on fat distribution and fasting lipids and glucose
homeostasis. The observed preservation of subcutaneous fat
during PRT suggests that this type of exercise did not promote
or exacerbate lipoatrophy. Overall, we saw no evidence of
improvement in metabolic and morphologic outcomes with either
creatine supplementation or exercise. Because renal function is
impaired in some patients with HIV infection [54], clinicians
should be aware of the possibility that elevations in serum
creatinine may occur in patients using creatine supplementation.
In summary, in this randomized, placebo-controlled trial of the
effects of progressive resistance training with and without creatine
supplementation in HIV-positive subjects, significant gains in
strength were achieved with 12 weeks of PRT with no further
benefit from creatine. The medical use of creatine supplementa-
tion in this population may be limited to aesthetic purposes, rather
than to improve functional capacity. However, the efficacy and
safety of PRT demonstrates its potential therapeutic benefit in
preventing or reversing muscle weakness.
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